Related Experiment Video
Updated: Jun 25, 2026
A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
Published on: March 15, 2016
In vivo method for establishing synergy between antibodies to epidermal growth factor receptor and vascular
James R Tonra1, Marie Prewett, Erik Corcoran
1ImClone Systems Inc, New York, NY, USA.
Abstract:
Targeted therapy for cancer is shifting towards an approach of inhibiting multiple pathways, justified in part by the ability of cancer cells to overcome the inhibition of a single pathway. However the literature is replete with preclinical data supporting the anticancer potential of numerous combinations of targeted agents, making it difficult to select the combination strategies to invest in through clinical development. One characteristic of a combination strategy that can be utilized for prioritization is synergy. Synergy indicates that the effect of the combination is greater than that predicted from the monotherapy potencies. Here we describe a detailed method for establishing synergy between two treatments in vivo. We utilized this method to establish that antibodies targeting the epidermal growth factor receptor and vascular endothelial growth factor receptor-2 are synergistic with regard to antitumor effects, in a BxPC-3 subcutaneous xenograft model for pancreatic cancer.
Insights
Combining targeted cancer therapies is crucial for overcoming resistance. This study demonstrates a method to identify synergistic drug combinations, showing that targeting both epidermal growth factor receptor and vascular endothelial growth factor receptor-2 enhances antitumor effects in pancreatic cancer models.
Area of Science:
- Oncology
- Pharmacology
- Cancer Research
Background:
- Targeted cancer therapy is evolving towards multi-pathway inhibition due to cancer cell resistance.
- Numerous preclinical combination studies exist, complicating clinical development prioritization.
- Synergy, where a combination's effect exceeds monotherapy predictions, is a key prioritization factor.
Purpose of the Study:
- To present a detailed in vivo method for establishing synergy between two targeted cancer treatments.
- To evaluate the synergistic antitumor effects of combined epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor-2 (VEGFR2) inhibition.
Main Methods:
- Developed and applied a detailed in vivo methodology to assess drug combination synergy.
- Utilized a BxPC-3 subcutaneous xenograft model for pancreatic cancer in preclinical studies.
Main Results:
- Demonstrated a validated method for establishing synergy between targeted cancer therapies in vivo.
- Established that antibodies targeting EGFR and VEGFR2 exhibit synergistic antitumor effects in the tested pancreatic cancer model.
Conclusions:
- The developed method provides a robust approach for prioritizing targeted therapy combinations for clinical development.
- Combined EGFR and VEGFR2 inhibition shows significant synergistic potential against pancreatic cancer, warranting further investigation.
More Related Videos
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
08:28Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025